We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!

Mr Vinagolu Rajasekhar

Senior Research Scientist

TM London Day Two

Thursday, 7th December 2017

14.40 | How To Advance PDX Tumour Biology Platforms Towards Enhancing Present Cancer Therapy Approaches?

Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service.  Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials.

Vinagolu spoke at

Similar Speakers

Mr David Lim

37 events , Science , Health

Mr John Robinson

16 events , Health